pSivida Corp Announces Interim Data From Investigator-Sponsored Uveitis Study
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced interim data from an investigator-sponsored Phase I/II study of pSivida’s injectable micro-insert in patients with posterior uveitis. The same micro-insert is being marketed in the EU as ILUVIEN® for the treatment of chronic Diabetic Macular Edema (DME) considered insufficiently responsive to available therapies by pSivida’s collaborative partner, Alimera Sciences. The uveitis application is being independently developed by pSivida.
Help employers find you! Check out all the jobs and post your resume.
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for the treatment of back-of-the-eye diseases, today announced interim data from an investigator-sponsored Phase I/II study of pSivida’s injectable micro-insert in patients with posterior uveitis. The same micro-insert is being marketed in the EU as ILUVIEN® for the treatment of chronic Diabetic Macular Edema (DME) considered insufficiently responsive to available therapies by pSivida’s collaborative partner, Alimera Sciences. The uveitis application is being independently developed by pSivida.
Help employers find you! Check out all the jobs and post your resume.